September 23, 2016: Since Dublin-based Allergan is in a buying mood, having completed a string of deals in the last few months, why not a big merger with Gilead. Kevin Kedra, an analyst with Gabelli, recently argued that Allergan was “playing chess while the market is playing checkers."
September 23, 2016: Sanofi recently lost out in a bid to acquire Medivation to Pfizer. Part of the rationale behind Sanofi’s hostile takeover bid was to expand into the oncology market, because Sanofi’s domination in the diabetes market is weakening.
September 23, 2016: Allergan's recent acquisitions of the Bay Area’s Tobira and San Diego-based Akarna Therapeutics has turned the spotlight on NASH and other liver diseases.
September 23, 2016: The months-long drama involving Sarepta’s eteplilrsen for DMD and the FDA is not over, despite the drug’s accelerated approval earlier this week.